Yang Lijun, Qian Jing, Yang Bo, He Qiaojun, Wang Jiajia, Weng Qinjie
Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Zhejiang Center for Drug and Cosmetic Evaluation, Hangzhou, China.
Front Pharmacol. 2021 Sep 30;12:721156. doi: 10.3389/fphar.2021.721156. eCollection 2021.
Stroke is the third most common disease all over the world, which is regarded as a hotspot in medical research because of its high mortality and morbidity. Stroke, especially ischemic stroke, causes severe neural cell death, and no effective therapy is currently available for neuroregeneration after stroke. Although many therapies have been shown to be effective in preclinical studies of ischemic stroke, almost none of them passed clinical trials, and the reasons for most failures have not been well identified. In this review, we focus on several novel methods, such as traditional Chinese medicine, stem cell therapy, and exosomes that have not been used for ischemic stroke till recent decades. We summarize the proposed basic mechanisms underlying these therapies and related clinical results, discussing advantages and current limitations for each therapy emphatically. Based on the limitations such as side effects, narrow therapeutic window, and less accumulation at the injury region, structure transformation and drug combination are subsequently applied, providing a deep understanding to develop effective treatment strategies for ischemic stroke in the near future.
中风是全球第三大常见疾病,因其高死亡率和高发病率而被视为医学研究的热点。中风,尤其是缺血性中风,会导致严重的神经细胞死亡,目前尚无有效的中风后神经再生治疗方法。尽管许多疗法在缺血性中风的临床前研究中已显示出有效性,但几乎没有一种疗法能通过临床试验,而且大多数失败的原因尚未明确。在这篇综述中,我们聚焦于几种近几十年来才开始用于缺血性中风的新方法,如传统中药、干细胞疗法和外泌体。我们总结了这些疗法背后的基本机制及相关临床结果,并着重讨论了每种疗法的优势和当前的局限性。基于副作用、治疗窗口狭窄以及在损伤区域积累较少等局限性,随后应用了结构改造和药物联合,以期为在不久的将来开发有效的缺血性中风治疗策略提供深入理解。